Company Profile
PepGen Stock Price, News & Catalysts
- Ticker:
- PEPG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.93 USD (+2.61%)
Close
Last updated: November 19, 2026
100M USD
Market cap
Why the stock is moving
As of Nov 19, 2026, PEPG closed up 2.61% at $3.93. No new same-company headline was identified in the current news window.
Company overview
Oligonucleotide Delivery Company
PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle.
PGN-EDODM1
PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression.
FREEDOM2
The FREEDOM2 study is evaluating multiple ascending doses, with early cohorts assessing safety, splice correction, and functional biomarkers.
Dose and Extension Strategy
PepGen is using FREEDOM2 dose cohorts and the FREEDOM open-label extension to define activity, durability, and a path toward an end-of-Phase 2 regulatory meeting for PGN-EDODM1.
Future catalysts
- Interim FREEDOM-OLE safety and clinical data in January 2027.
- Results from the 12.5 mg/kg FREEDOM2-DM1 cohort in the first half of 2027.
- End-of-Phase 2 meeting for PGN-EDODM1 in the second half of 2027, pending removal of the partial clinical hold.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PepGen (PEPG)?
PepGen (PEPG) most recently closed at 3.93 USD, a +2.61% move versus the previous session.
What is the market cap of PepGen (PEPG)?
PepGen currently has a market capitalization of 100M USD on BioPharmSignal.
What does PepGen do?
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2 study is evaluating...
On which exchange is PEPG stock listed?
PepGen (PEPG) is associated with NASDAQ, United States, Biopharma.
What is PGN-EDODM1?
End-of-Phase 2 meeting for PGN-EDODM1 in the second half of 2027, pending removal of the partial clinical hold.
Which conditions is PepGen targeting with PGN-EDODM1?
End-of-Phase 2 meeting for PGN-EDODM1 in the second half of 2027, pending removal of the partial clinical hold.
How does PepGen describe recent progress with PGN-EDODM1?
End-of-Phase 2 meeting for PGN-EDODM1 in the second half of 2027, pending removal of the partial clinical hold.
What is FREEDOM-OLE?
Interim FREEDOM-OLE safety and clinical data in January 2027.
